N/A N=107 Acceptance and Commitment Therapy to Improve Social Support for Veterans With PTSD
Post-traumatic Stress Disorder
Primary: Change in the Social Adjustment Scale-Self Report — 3.384; 3.344; 2.974; 2.99 Units on a Scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Biolinq External Interferent Protocol
Diabetes · Diabetes Mellitus
Primary: Number of Samples Where YSI Values Matched the Biolinq Sensor's Color During the First Hour Post Acetaminophen (APAP) Intake. — 112 Paired Samples - YSI to Biolinq
Phase 2 N=30 Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
Biliary Tract Cancer
Primary: Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab — 4 Participants
Phase 3 N=501 Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change From Baseline in OA Pain in the Target Knee (Pain NRS) — -2.24; -2.49 units on a scale — p=0.185
N/A N=24 Sevoflurane Concentrations in Children
Anesthetic · Sevoflurane · Age
Primary: Ratios of the Inspired to Expired Sevoflurane Concentrations During Induction of Anesthesia — 0; 0; 0.684; 0.6615 ratio
Phase 1 N=60 Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
RSV Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants
N/A N=30 SinuSonic for ETD and Facial Pain: Acoustic Vibration + Oscillating Expiratory Pressure
Eustachian Tube Dysfunction · Facial Pain
Primary: Eustachian Tube Dysfunction (ETD) Symptom Visual Analog Scale (VAS) - Total Score — 59.6 score on a scale
N/A N=63 PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men
Risk Reduction
Primary: Number of Participants Indicating the Intervention Was Acceptable — 37 Participants
N/A N=20 A Net Ultrafiltration Challenge to Predict Preload-dependence (UF CHALLENGE)
Acute Kidney Injury
Primary: Diagnostic Performance of the Net Ultrafiltration (UF NET) Challenge to Detect de Novo Preload Dependence — 0.74 Proportion probability (0 to 1) — p=0.02
Phase 2 N=317 A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Dry Eye Disease
Primary: Mean Change From Baseline to Week 8 in Symptoms of Dry Eye Assessed by Symptom Assessment in Dry Eye (SANDE) Global Score — -19.6; -20.7; -15.5 score on a scale — p==0.076
N/A N=224 Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations
Ischemic Heart Disease · Hopelessness · Physical Activity
Primary: Minutes/Day of Physical Activity (Measured by Actigraph) — 6.7; 4.8; 8.6 minutes/day
Phase 2 N=74 Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Prostate Cancer
Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months
N/A N=69 Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain
Chronic Pelvic Pain · Endometriosis
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form (SF) 4a Between Groups — 59.2; 63.4 t-scores — p=0.038
N/A N=132 an On-demand Program to EmpoweR Active Self-management (OPERAS)
Joint Disease · Rheumatoid Arthritis
Primary: Patient Activation Measure — 65.1; 68.3; 69.8; 67.1 score on a scale — p=0.05
Phase 2 N=33 Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
Colorectal Cancer
Primary: Major Pathological Response (MPR) Rate — 89.7 Percentage of Participants